×
About 4,393 results

ALLMedicine™ Choroidal Neovascularization Center

Research & Reviews  1,416 results

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD
https://clinicaltrials.gov/ct2/show/NCT03024424

Aug 12th, 2022 - The goals of this study are: To assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic counseling in persona...

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
https://clinicaltrials.gov/ct2/show/NCT04774926

Aug 12th, 2022 - This is a one-year, open-label, single arm, multicenter, phase IV study in patients with untreated active subfoveal Choroidal Neovascularization (CNV) secondary to wAMD The study consists of a screening period of up to 2 weeks and a treatment peri...

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT04047472

Aug 12th, 2022 - To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
https://clinicaltrials.gov/ct2/show/NCT04698850

Aug 10th, 2022 - Retinal angiomatous proliferation (RAP) is one of the variants of wet form of age-related macular degeneration (wAMD). Neovascularization in RAP grows from the retinal deep capillary plexus into the subretinal space where it forms subretinal and l...

Animal Models of Choroidal Neovascularization: A Systematic Review.
https://doi.org/10.1167/iovs.63.9.11
Investigative Ophthalmology & Visual Science; Fabian-Jessing BK, Jakobsen TS et. al.

Aug 10th, 2022 - Animal models of choroidal neovascularization (CNV) are extensively used to characterize the pathophysiology of chorioretinal diseases with CNV formation and to evaluate novel treatment strategies. This systematic review aims to give a detailed ov...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  241 results

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT04047472

Aug 12th, 2022 - To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
https://clinicaltrials.gov/ct2/show/NCT04774926

Aug 12th, 2022 - This is a one-year, open-label, single arm, multicenter, phase IV study in patients with untreated active subfoveal Choroidal Neovascularization (CNV) secondary to wAMD The study consists of a screening period of up to 2 weeks and a treatment peri...

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD
https://clinicaltrials.gov/ct2/show/NCT03024424

Aug 12th, 2022 - The goals of this study are: To assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic counseling in persona...

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
https://clinicaltrials.gov/ct2/show/NCT04698850

Aug 10th, 2022 - Retinal angiomatous proliferation (RAP) is one of the variants of wet form of age-related macular degeneration (wAMD). Neovascularization in RAP grows from the retinal deep capillary plexus into the subretinal space where it forms subretinal and l...

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT04239027

Aug 8th, 2022 - Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead to hemorrhage, fl...

see more →

News  93 results

Reevaluating the Safety of Brolucizumab for Treating Wet Age-Related Macular Degeneration
https://www.medscape.com/viewarticle/970116

Mar 11th, 2022 - Age-related macular degeneration (AMD) is a disease of the macula and a leading cause of vision loss.[1] Neovascular AMD, also known as wet AMD, is a type of AMD that is characterized by choroidal neovascularization, which results in the leakage o...

Skill Checkup: A 61-Year-Old Man With Central Visual Acuity Blurring
https://reference.medscape.com/viewarticle/956969

Sep 24th, 2021 - The Skill Checkup series provides a quick, case-style interactive quiz highlighting key guidelines- and evidence-based information to inform clinical practice. A 61-year-old man presents with painless progressive blurring of central visual acuity ...

Skill Checkup: A 61-Year-Old Man With Central Visual Acuity Blurring
https://www.medscape.com/viewarticle/956969

Sep 24th, 2021 - The Skill Checkup series provides a quick, case-style interactive quiz highlighting key guidelines- and evidence-based information to inform clinical practice. A 61-year-old man presents with painless progressive blurring of central visual acuity ...

FDA Approves First Biosimilar for Ranibizumab Intravitreal Injections, nAMD
https://www.medscape.com/viewarticle/959087

Sep 20th, 2021 - The US Food and Drug Administration (FDA) has approved the first biosimilar for ophthalmology, Byooviz (ranibizumab-nuna), which will be indicated for neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein ...

Intravitreal Anti-VEGFs Not Linked to Major Cardiovascular Adverse Events
https://www.medscape.com/viewarticle/949803

Apr 23rd, 2021 - NEW YORK (Reuters Health) - Intravitreal anti-vascular endothelial growth factor (VEGF) drugs were not associated with an increase in major adverse cardiovascular events (MACEs) in a new systematic review and meta-analysis. The results update an e...

see more →

Patient Education  2 results see all →